Free exam prep

BCSCP Board Certified Sterile Compounding Pharmacist

5.1 Category 1 Beyond-Use Dating & Storage Limitations

Key Takeaways

Category 1 CSPs are prepared in an ISO Class 5 Primary Engineering Control (PEC), usually one located in an unclassified Segregated Compounding Area (SCA).
The beyond-use date for a Category 1 CSP is strictly capped at $\le 12$ hours at controlled room temperature ( $20^\circ\text{C}$ to $25^\circ\text{C}$ ) or $\le 24$ hours in a refrigerator ( $2^\circ\text{C}$ to $8^\circ\text{C}$ ).
Freezing Category 1 CSPs is strictly prohibited; freezing cannot be utilized to extend beyond-use dating in an SCA.
The short BUD limits reflect the absence of an ISO 7 cleanroom buffer area, which exposes the primary engineering control to variable ambient bioburden and airborne particulate fluctuations.

Last updated: September 2026

Beyond-Use Dating Fundamentals in Category 1 Environments

A Beyond-Use Date (BUD) represents the date and time after which a compounded sterile preparation must not be administered, stored, or transported. Under USP General Chapter <797>, a BUD is assigned based on two distinct considerations:

Microbiological Sterility Assurance: The likelihood that viable microorganisms have entered or multiplied within the preparation during compounding or storage.
Chemical and Physical Stability: The degradation rate of the active pharmaceutical ingredient (API), compatibility of excipients, and integrity of the container-closure system.

Important

A BUD can never exceed the shortest chemical stability limit of the drug substance or the manufacturer expiration date of any starting commercial component.

Category 1 Temperature-Specific BUD Allowances

Category 1 CSPs are defined by their preparation in an ISO Class 5 Primary Engineering Control (such as a LAFW, BSC, or CAI) situated inside an unclassified Segregated Compounding Area (SCA) or a cleanroom suite that does not meet full Category 2 criteria.

The Category 1 BUD Matrix

Storage Temperature	Temperature Range	Maximum Allowable Category 1 BUD
Controlled Room Temperature	$20^\circ\text{C}$ to $25^\circ\text{C}$ ( $68^\circ\text{F}$ to $77^\circ\text{F}$ )	$\le 12$ hours
Refrigerated Storage	$2^\circ\text{C}$ to $8^\circ\text{C}$ ( $36^\circ\text{F}$ to $46^\circ\text{F}$ )	$\le 24$ hours
Frozen Storage	$-25^\circ\text{C}$ to $-10^\circ\text{C}$ ( $-13^\circ\text{F}$ to $14^\circ\text{F}$ )	PROHIBITED (Cannot be frozen)

The Absolute Ban on Freezing

A major area of testing on the BCSCP exam is the prohibition of frozen storage for Category 1 CSPs. In previous iterations of USP <797>, low-risk preparations could occasionally be assigned frozen dating. Under the 2023 revision, Category 1 preparations can never be frozen. The rationale is biological: while freezing halts microbial replication, it does not destroy bacterial or fungal contaminants that may have entered the preparation during compounding in an unclassified ambient environment.

Clinical Applications and Operational Limits

Category 1 compounding is tailored for acute, rapid-turnaround clinical workflows:

Emergency Department Satellite Pharmacies: Immediate preparation of broad-spectrum antibiotic infusions (e.g., piperacillin/tazobactam, cefepime) or electrolyte boluses.
Ambulatory Surgery Centers: Daily batching of local anesthetic blocks or ophthalmic irrigations.
Outpatient Chemotherapy Infusion Centers: Patient-specific monoclonal antibody and antineoplastic infusions compounded in a C-SCA for same-day administration.

Operational Pitfall: Anticipatory Batching Traps

A hospital pharmacy compounding 50 doses of cefazolin for surgical prophylaxis cannot prepare doses 48 hours in advance using a Category 1 SCA, even if kept refrigerated. Doses exceeding 24 hours refrigerated must either be compounded under full Category 2 cleanroom conditions or discarded.

Immediate-Use Compounding Exemptions vs. Category 1 CSPs

Compounding personnel must clearly separate Category 1 CSPs from preparations made under the immediate-use provision of USP <797>. That provision covers CSPs made for direct and immediate administration that meet all seven conditions in Section 1.3 (see 1.4):

Operational Feature	Immediate-Use Exemption	Category 1 CSPs	Category 2 CSPs
Primary Engineering Control (PEC)	None required; prepared at clinical bedside, ICU, OR, or trauma bay	Mandatory ISO Class 5 PEC (LAFW, BSC, CAI, or CACI)	Mandatory ISO Class 5 PEC (LAFW, BSC, CAI, or CACI)
Secondary Engineering Control (SEC)	Uncontrolled clinical ambient environment	Segregated Compounding Area (SCA) or unclassified room	ISO Class 7 Buffer Room with ISO Class 8 (or 7) Ante-Room
Maximum Component Limit	Not more than 3 different sterile products; USP <800> still governs hazardous drugs	No component count limit; sterile or nonsterile components	No component count limit; sterile or nonsterile components
Preparation Process Limit	No set preparation time; aseptic technique and SOPs required	Standard compounding batch or individual preparation	Standard compounding batch or individual preparation
Administration Timing	Administration must begin within 4 hours of preparation start	Administration governed by assigned BUD (12h RT / 24h Fridge)	Administration governed by Category 2 BUD grid (up to 45/90 days)
Storage Conditions Permitted	Held only until administration begins (within 4 hours); may be batched for more than one patient if every condition is met	Controlled Room Temp ( $\le 12\,\text{h}$ ) or Refrigerated ( $\le 24\,\text{h}$ )	Room Temp, Refrigerated, or Frozen per matrix
Freezing Permitted	Strictly prohibited	Strictly prohibited	Permitted (up to 45, 60, or 90 days per matrix)

Temperature Standards, Monitoring Devices & Excursion Management (USP <659>)

Maintaining the physical and chemical stability of CSPs requires precise environmental temperature control. USP General Chapter <659> (Packaging and Storage Requirements) codifies standardized temperature ranges that govern compounding facilities, cleanrooms, and medical storage appliances:

Controlled Room Temperature: Maintained thermostatically between $20^\circ\text{C}$ and $25^\circ\text{C}$ ( $68^\circ\text{F}$ to $77^\circ\text{F}$ ), with temporary excursions permitted between $15^\circ\text{C}$ and $30^\circ\text{C}$ .
Refrigerated (Cold): Maintained thermostatically between $2^\circ\text{C}$ and $8^\circ\text{C}$ ( $36^\circ\text{F}$ to $46^\circ\text{F}$ ).
Freezer: Maintained thermostatically between $-25^\circ\text{C}$ and $-10^\circ\text{C}$ ( $-13^\circ\text{F}$ to $14^\circ\text{F}$ ).

Temperature Excursion Management & Mean Kinetic Temperature (MKT)

When a storage appliance experiences an excursion outside certified limits (e.g., a refrigerator temperature rises to $13^\circ\text{C}$ ), the Designated Person must execute a formal deviation investigation:

Immediate Physical Quarantine: All CSPs stored within the compromised appliance must be quarantined in an alternate calibrated appliance.
Chemical Stability Assessment: Evaluate whether active drug molecules underwent thermal degradation, denaturation, or hydrolysis.
Mean Kinetic Temperature (MKT): MKT expresses a fluctuating temperature history as a single equivalent temperature, using the Arrhenius relationship. USP <659> uses it for manufactured products. For example, controlled cold temperature (2-8 °C) allows excursions of 0-15 °C if the calculated MKT stays at or below 8 °C. For a CSP, USP <797> 19.1 sets the rule: when a CSP is known to have been exposed outside its storage limits, a designated person must decide, from the literature or by testing, whether it keeps its integrity and quality. If that cannot be determined, the CSP is discarded. Freezing a refrigerated protein or emulsion is a separate physical failure that MKT cannot fix.

Test Your Knowledge

A hospital satellite pharmacy prepares a patient-specific infusion of piperacillin/tazobactam 3.375 g in 100 mL 0.9% sodium chloride injection inside an ISO Class 5 laminar airflow workbench situated in an unclassified Segregated Compounding Area (SCA). The prescriber requests that multiple doses be batched in advance and frozen for upcoming administrations over the weekend. Under the 2023 revision of USP General Chapter <797>, how should the pharmacist assign the beyond-use date and storage conditions for this preparation?

Assign a maximum beyond-use date of 12 hours at controlled room temperature or 24 hours under refrigeration; freezing is strictly prohibited for Category 1 compounded sterile preparations.

Assign a beyond-use date of 45 days stored in a certified freezer at -20°C, provided the infusion is compounded using sterile commercial starting components.

Assign a beyond-use date of 48 hours under refrigeration and 14 days frozen, provided a 0.22-micron filter is utilized during reconstitution.

Assign a beyond-use date of 24 hours at controlled room temperature or 72 hours under refrigeration, because the preparation is batched for a single patient.

Test Your Knowledge

During a code in the ICU, a clinician mixes a norepinephrine infusion at the bedside from vials and a bag of dextrose 5%, as an immediate-use CSP. Placing central access is difficult, so the infusion cannot start right away. What USP <797> limit applies?

The preparation may be stored up to 12 hours at room temperature or 24 hours refrigerated before administration starts

Administration must begin within 4 hours after preparation started, or the preparation must be promptly and safely discarded

Administration may begin within 24 hours if the bag is moved into an ISO Class 5 laminar airflow workbench

Preparation must be finished within 1 hour and administration within 2 hours, using no more than two products

Test Your Knowledge

A cleanroom refrigerator storing compounded sterile preparations experiences an electrical malfunction over a holiday weekend. The continuous automated monitoring system logs temperature readings rising from 4.5°C to 13.5°C for a continuous duration of 14 hours before returning to 5.0°C. Which of the following evaluations and actions is mandatory under USP standards before determining whether any quarantined preparations may be salvaged?

All refrigerated preparations may remain in circulation without investigation if the arithmetic mean temperature over the 24-hour cycle remained below 10.0°C.

The preparations must be immediately frozen at -20°C to halt microbial proliferation and arrest thermal drug degradation.

All affected preparations must be quarantined immediately, and the Designated Person must assess the excursion against manufacturer stability data, Mean Kinetic Temperature calculations, and maximum allowable excursion limits before release or destruction.

The beyond-use dates of all stored preparations must be automatically halved without consulting drug-specific degradation kinetics or packaging integrity.

Sections you finish are checked off in the contents.

Up Next

5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components

Continue learning